secwatch.observer — SEC 8-K summary
======================================

Issuer:     TALPHERA, INC. (TLPH)
CIK:        0001427925
Form:       8-K
Filed at:   2024-08-14T23:59:59+00:00
Accession:  0001437749-24-026815
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Talphera Q2 net loss $3.8M; CMO Palmer retiring Oct 1, succeeded by Dr. Aslam
-----------------------------------------------------------------------------

- Net loss $3.8M ($0.15 loss per share) vs $4.4M ($0.40 loss) in Q2 2023; cash $14.0M.
- NEPHRO CRRT registrational study screening initiated; enrolling 166 patients at up to 14 U.S. sites.
- Pamela Palmer, co-founder and CMO, to retire Oct 1; Dr. Shakil Aslam (current CDO) to become CMO.
- Combined R&D and SG&A expenses rose to $4.3M from $4.2M year-over-year; no DSUVIA expenses.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1427925/000143774924026815/0001437749-24-026815-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1427925/000143774924026815/acrx20240814_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-026815

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer